Loading
Cancer / Immune Checkpoint Inhibitors / COVID 19 Vaccination · Observational Study
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
COVICI-SURV is a completed, nationwide retrospective cohort study designed to evaluate whether COVID-19 vaccination around immune checkpoint inhibitor initiation is associated with survival in adults with cancer. No results are posted in this registry record; the study is registered with planned follow-up extending to 31 December 2024 for all-cause mortality.
Observational. Cancer, Immune Checkpoint Inhibitors, COVID-19 Vaccination, Survival; age from 18 Years. Intervention: National ICI initiator cohort. Compared with: No COVID-19 vaccination within the 100-day window. n = 95,015. 1 site: France.
COVICI-SURV is a completed, nationwide retrospective cohort study designed to evaluate whether COVID-19 vaccination around immune checkpoint inhibitor initiation is associated with survival in adults with cancer. No results are posted in this registry record; the study is registered with planned follow-up extending to 31 December 2024 for all-cause mortality.
Secondary outcomes (cancer-specific mortality, non-COVID-19 mortality, progression-free survival) have different follow-up endpoints and are not detailed in this record.
The source did not state who this applies to in practice.
This is a completed observational cohort study with no results yet posted; the registry record describes design and methods only, making it impossible to assess evidence strength from outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07729241). This is a study registration, not published results. Lead sponsor: Groupe Hospitalier Pitie-Salpetriere. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 95015 participants (ACTUAL). Conditions: Cancer, Immune Checkpoint Inhibitors, COVID-19 Vaccination, Survival. Primary outcome measures: All-cause mortality after ICI initiation , From ICI initiation to death or administrative censoring on 31 December 2024. Brief summary: COVICI-SURV is a nationwide, retrospective observational cohort study using the French national health data system (SNDS) to evaluate whether COVID-19 vaccination, particularly mRNA vaccination, received within 100 days before or after immune checkpoint inhibitor (ICI) initiation is associated with survival among adults with cancer. The cohort includes 95,015 adults initiating anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy between 28 December 2020 and 22 March 2023. Pre-ICI vaccination is analysed using inverse probability of treatment weighting, and post-ICI vaccination among patients without COVID-19 vaccination in the preceding 100 days is analysed using a cloning-censoring-weighting target-trial emulation. The primary outcome is all-cause mortality; secondary outcomes include cancer-specific mortality, non-COVID-19 mortality and real-world progression-free survival. Follow-up extends to 31 December 2024 for all-cause mortality and to 31 December 2023 for cause-specific mortality.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.